Cellectis S.A. (CLLS) is currently trading at $2.89 with a Wall Street consensus price target of $7.6, implying potential upside of 163.0% over the next 12 months. 5 analysts currently cover CLLS, with a consensus rating of Buy - 80% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $10.0, while the most cautious has a target of $4.0.
CLLS operates in the Healthcare sector with a market capitalisation of $291M. The stock is down 39.8% year-to-date and is currently trading near the lower end of its 52-week range of $2.35 – $5.48.
Other Healthcare stocks with comparable size and valuation.
Upgrade/downgrade history for CLLS, with each firm's 90-day track record across all stocks we track. See full firm rankings →
Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.
Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.
StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.
View Full Rankings →